Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology.
暂无分享,去创建一个
[1] H. Braak,et al. Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff , 2017, Journal of Parkinson's disease.
[2] Manuel B. Graeber,et al. PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease , 2010, Science Translational Medicine.
[3] A. Schapira,et al. Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications , 2018, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[4] K. Marder,et al. Pilot association study of the β‐glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity , 2005, Movement disorders : official journal of the Movement Disorder Society.
[5] K. Lim,et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.
[6] T. Südhof,et al. Cell Biology and Pathophysiology of α-Synuclein. , 2018, Cold Spring Harbor perspectives in medicine.
[7] M. Beal,et al. Somatic mitochondrial DNA mutations in early parkinson and incidental lewy body disease , 2012, Annals of neurology.
[8] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[9] C. Tanner,et al. Prevalence of Parkinson’s disease across North America , 2018, npj Parkinson's Disease.
[10] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[11] C. Tanner,et al. Concordance for Parkinson's disease in twins: A 20‐year update , 2019, Annals of neurology.
[12] Sonja W. Scholz,et al. Parkinson’s disease genetics: identifying novel risk loci, providing causal insights and improving estimates of heritable risk , 2018, bioRxiv.
[13] A. Nicholas,et al. Nonmotor symptoms in Parkinson's disease: expanding the view of Parkinson's disease beyond a pure motor, pure dopaminergic problem. , 2013, Neurologic clinics.
[14] C. Tanner,et al. Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. , 2012, Parkinsonism & related disorders.
[15] K. Marder,et al. Pooled analysis of tobacco use and risk of Parkinson disease. , 2007, Archives of neurology.
[16] Michael Jerrett,et al. A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. , 2007, Environmental research.
[17] C. Tanner,et al. Dietary fat intake, pesticide use, and Parkinson's disease. , 2014, Parkinsonism & related disorders.
[18] T. Sherer,et al. The rotenone model of Parkinson's disease: genes, environment and mitochondria. , 2003, Parkinsonism & related disorders.
[19] M. Tansey,et al. The role of innate and adaptive immunity in Parkinson's disease. , 2013, Journal of Parkinson's disease.
[20] R. Nussbaum,et al. Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.
[21] Lianne Sheppard,et al. Dose-dependent progression of parkinsonism in manganese-exposed welders , 2017, Neurology.
[22] Michael Johnson,et al. Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis , 2019, Trends in Neurosciences.
[23] J. Olsen,et al. Parkinson's disease and other neurodegenerative disorders among welders: A Danish cohort study , 2012, Movement disorders : official journal of the Movement Disorder Society.
[24] Xiang Gao,et al. Prospective study of dietary pattern and risk of Parkinson disease. , 2007, The American journal of clinical nutrition.
[25] T. Sherer,et al. Nilotinib – Differentiating the Hope from the Hype , 2016, Journal of Parkinson's disease.
[26] C. Tanner,et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. , 2019, Neurology.
[27] H. Berendse,et al. Patterns of α-synuclein pathology in incidental cases and clinical subtypes of Parkinson's disease. , 2012, Parkinsonism & related disorders.
[28] A. Reunanen,et al. Polychlorinated biphenyls in prospectively collected serum and Parkinson's disease risk , 2012, Movement disorders : official journal of the Movement Disorder Society.
[29] J. Jankovic,et al. Targeting α-Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics , 2019, Drugs.
[30] D. Alessi,et al. LRRK2 kinase in Parkinson's disease , 2018, Science.
[31] J. Nutt,et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease , 2010, Nature Genetics.
[32] H. Shill,et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction , 2009, Acta Neuropathologica.
[33] S. Goldman. Environmental toxins and Parkinson's disease. , 2014, Annual review of pharmacology and toxicology.
[34] Guodong Huang,et al. Age-Dependent Dopaminergic Neurodegeneration and Impairment of the Autophagy-Lysosomal Pathway in LRRK-Deficient Mice , 2017, Neuron.
[35] P. Brundin,et al. Prying into the Prion Hypothesis for Parkinson's Disease , 2017, The Journal of Neuroscience.
[36] C. Tanner,et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease , 2005, Neurology.
[37] P. Cobbold,et al. Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson’s Disease , 2020, Brain sciences.
[38] C. Tanner,et al. Rotenone, Paraquat, and Parkinson’s Disease , 2011, Environmental health perspectives.
[39] H. Birnbaum,et al. Direct costs and survival of medicare beneficiaries with early and advanced Parkinson's disease. , 2012, Parkinsonism & related disorders.
[40] C. Tanner,et al. The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk , 2014, Alzheimer's & Dementia.
[41] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[42] H. Adami,et al. Physical activity and risk of Parkinson's disease in the Swedish National March Cohort. , 2015, Brain : a journal of neurology.
[43] B. Bloem,et al. The Emerging Evidence of the Parkinson Pandemic , 2018, Journal of Parkinson's disease.
[44] C. Tanner,et al. Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.
[45] W. Poewe,et al. Mortality in Parkinson's disease: A 38‐year follow‐up study , 2015, Movement disorders : official journal of the Movement Disorder Society.
[46] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[47] C. Tanner,et al. Solvent exposures and parkinson disease risk in twins , 2012, Annals of neurology.
[48] Xuemei Huang,et al. Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein , 2019, Science Signaling.
[49] L. Sheppard,et al. [18F]FDOPA positron emission tomography in manganese‐exposed workers , 2017, Neurotoxicology.
[50] O. Sánchez,et al. Role of Connexins 30, 36, and 43 in Brain Tumors, Neurodegenerative Diseases, and Neuroprotection , 2020, Cells.
[51] Daniela Berg,et al. Advances in markers of prodromal Parkinson disease , 2016, Nature Reviews Neurology.
[52] T. Dawson,et al. PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease , 2011, Cell.
[53] S. Schneider,et al. Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature , 2017, Movement disorders : official journal of the Movement Disorder Society.
[54] D. Twelves,et al. Systematic review of incidence studies of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[55] C. Tanner,et al. Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease. , 2015, Environment international.
[56] J. Volkmann,et al. Parkinson disease , 2017, Nature Reviews Disease Primers.
[57] G. Di Trapani,et al. The Multifaceted Roles of DJ-1 as an Antioxidant. , 2017, Advances in experimental medicine and biology.
[58] A. Ascherio,et al. The epidemiology of Parkinson's disease: risk factors and prevention , 2016, The Lancet Neurology.
[59] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[60] T. Warner,et al. Association between diabetes and subsequent Parkinson disease , 2018, Neurology.
[61] L. Leclair-Visonneau,et al. Is Parkinson’s disease a chronic low-grade inflammatory bowel disease? , 2019, Journal of Neurology.
[62] C. Adler,et al. Does Parkinson’s disease start in the gut? , 2017, Acta Neuropathologica.
[63] M. Hannan,et al. Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts , 2018, Neurology.
[64] Suneil K. Kalia,et al. Disease‐modifying strategies for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[65] D. Morens,et al. Epidemiologic observations on Parkinson's disease , 1996, Neurology.
[66] G. Riboldi,et al. GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches , 2019, Cells.
[67] N. Gray,et al. Small-Molecule Inhibitors of LRRK2. , 2017, Advances in neurobiology.
[68] M. Smidt,et al. Entanglement of Genetics and Epigenetics in Parkinson’s Disease , 2019, Front. Neurosci..
[69] Patrizia Rizzu,et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.
[70] B. Ritz,et al. Head injury and risk for Parkinson disease , 2015, Neurology.